Development and characterisation of neutralising mouse-human chimeric anti-SARS-CoV monoclonal antibodies

Similar Items

• Development and characterisation of neutralising mouse-human chimeric anti-SARS-CoV monoclonal antibodies
  by: Hay, Kevin Anthony
  Published: (2013)
• Stability and neutralising capacity of SARS-CoV-2-specific antibodies in convalescent plasma
  by: Torsten Tonn, et al.
  Published: (2020-06-01)
• Understanding neutralising antibodies against SARS-CoV-2 and their implications in clinical practice
  by: Natalie Yan-Lin Pang, et al.
  Published: (2021-08-01)
• SARS-CoV-2 spike E484K mutation reduces antibody neutralisation
  by: Sonia Jangra, et al.
  Published: (2021-07-01)
• Anti-SARS-CoV-2 Vaccines and Monoclonal Antibodies Facing Viral Variants
  by: Ahlam Chaqroun, et al.
  Published: (2021-06-01)